Evommune Inc. picked up rights outside of greater China to an oral, preclinical VAV1-directed molecular glue degrader (MGD) ...

Qyuns Therapeutics Co. Ltd. is expanding its partnership with Caldera Therapeutics through a potential $780 million deal for ...

In the first 10 months of 2026, biopharma firms raised $98.5 billion across 898 financing transactions, up 58.5% from $62.14 billion across 958 financings in the same period in 2025. Despite the value ...

This summer’s U.S. FDA clearance of the oral pan-RAS inhibitor Rasonque (daraxonrasib) from Revolution Medicines Inc. provided hope for pancreatic ductal adenocarcinoma (PDAC) patients, and results ...

Despite a concerted effort to speed trial setup, the number of patients taking part in industry-sponsored clinical studies in ...

Qyuns Therapeutics Co. Ltd. is expanding its partnership with Caldera Therapeutics through a potential $780 million deal for a preclinical TL1A/IL-17 bispecific antibody program, adding a second Qyuns ...

Biopharma deal value fell 38.5% in the third quarter (Q3) of 2026 to $55.55 billion, down from the record $90.4 billion in Q2 ...

China’s Minghui Pharmaceutical secured a $110 million up-front payment from Aska Pharmaceutical Co. Ltd. in a Japan-only ...

Five weeks after winning U.S. FDA approval of Emcitate (tiratricol) to treat peripheral thyrotoxicosis in those with MCT8 ...

T-Therapeutics Ltd. has raised $133 million in an oversubscribed series B, providing the means to deliver clinical proof of concept for its T-cell receptor-CD3 bispecifics in solid tumors and ...

Abbvie Inc. is paying Nxera Pharma Co. Ltd. $100 million up front for worldwide rights to NXE-0033744, a phase II-ready oral EP4 receptor agonist designed to act locally in the gastrointestinal tract ...

For the third time this year, the U.S. CDC’s Advisory Committee on Immunization Practices (ACIP) canceled its regularly scheduled meeting last month due to ongoing litigation. The cancellation made ...